Nivolumab 240mg/20ml / Relatlimab 80mg/20ml solution for infusion vials
NHS hospitals in England used £61,117,447 of indicative cost of Nivolumab 240mg/20ml / Relatlimab 80mg/20ml solution for infusion vials in the 12 months to July 2026, about 0.2% of all hospital medicines spend. That is up 74.2% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Nivolumab 240mg/20ml / Relatlimab 80mg/20ml solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to July 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Nivolumab 240mg/20ml / Relatlimab 80mg/20ml solution for infusion vials most
By indicative cost over the 12 months to July 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| East And North Hertfordshire Nhs Trust | £4,588,793 |
| Leeds Teaching Hpls Nhs Trust | £4,539,715 |
| The Clatterbridge Cancer Centre Nhs Ft | £4,269,786 |
| Univ Hpl B/Ham Nhs Foundation Trust | £3,361,843 |
| Sheffield Teaching Hospitals Nhs Trust | £2,907,872 |
| Royal Cornwall Hospitals Nhs Trust | £2,699,290 |
| Lancashire T/Ing Hsp Nhs Foundation Trus | £2,515,248 |
| Guy's & St Thomas' Nhs Foundation Trust | £2,098,085 |
| Gloucestershire Hpls Nhs Foundation Trst | £2,042,872 |
| The Royal Wolverhampton Nhs Trust | £1,938,581 |
The primary-care picture
Nivolumab is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Nivolumab medicine page.